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Introduction
In mammals, fertility depends on the timely onset and cyclic 
secretion of the neurohormone gonadotropin-releasing hor-
mone (GnRH), which is secreted into the portal blood vessels of 
the pituitary gland by approximately 1,000 hypothalamic neu-
rons (1). Deficiency in hypothalamic GnRH impairs puberty and 
almost invariably leads to infertility, causing a genetic condition 
that is known as hypogonadotropic hypogonadism (HH) or, when 
combined with anosmia, as Kallmann syndrome (KS) (2). The 
previous analysis of a single human fetus from a family with chro-
mosome X–linked KS (3), combined with the analysis of mouse 
models with engineered genetic mutations, shows that defective 
GnRH neuron development can cause HH/KS (4). For example, 
we recently demonstrated that the class 3 semaphorin SEMA3A 
is essential for axon guidance during GnRH neuron develop-
ment in mice (5), and others subsequently identified mutations 
in SEMA3A in patients with KS (6, 7). These and other studies 
(8) show that genetic mouse models are valuable tools to iden-
tify candidate genes for HH/KS and elucidate how their mutation 
may compromise the formation of the GnRH neuron system in 
patients for whom the diagnosis of impaired GnRH secretion 
alone provides little insight into the disease mechanism (1). How-
ever, mutations have so far only been identified in approximately 
40% of HH/KS cases, partly because the small number of fami-
lies affected by this disease impedes genetic linkage studies, but 
also because sporadic mutations cannot be identified with link-
age studies, and some cases are probably oligogenic (8).
Here, we have combined exome sequencing of KS patients 
with bioinformatics, functional in vitro studies, and the pheno-
typing of genetically modified mice to identify SEMA3E as a 
gene that is essential for GnRH neuron development and that 
is affected in KS. The SEMA3E gene encodes a secreted class 3 
semaphorin that triggers repulsion of endothelial cells in spe-
cific vascular beds (9, 10) and modulates axonal growth and 
synaptic connectivity for the correct wiring of the CNS (11–13). 
Unexpectedly, we found that the SEMA3E mutation, rather 
than affecting axon guidance in the GnRH neuron system, 
instead compromised survival signaling in GnRH neurons via 
PI3 kinase. Accordingly, loss of SEMA3E or its receptor plexin 
D1 (PLXND1) in mice caused GnRH neuron apoptosis during 
the developmental window in which these neurons express 
PLXND1 and migrate through SEMA3E-expressing brain 
regions to reach the hypothalamus. SEMA3E-mediated survival 
signaling also relied on KDR, a receptor tyrosine kinase that was 
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Chd7, a gene previously implicated in KS. Our study further 
provides proof of principle that exome sequencing, when com-
bined with suitable in silico, in vitro, and in vivo animal models, 
can identify genetic pathways involved in GnRH neurodevelop-
ment and deficiency.
previously implicated as a coreceptor for PLXND1 in SEMA3E-
mediated axonal growth (11). Thus, our study has uncovered 
a novel role for SEMA3E as a neurotrophic factor that delivers 
essential survival signals for GnRH neurons via PLXND1 and 
KDR. Finally, we show that Sema3e interacts genetically with 
Figure 1. Exome sequencing identifies a SEMA3E point mutation in KS patients. (A) Pedigree of brothers affected by KS carrying a novel SEMA3E mutation. 
Circle denotes female; square denotes male; black square denotes affected male; arrows indicate the probands. (B) Sequence chromatograms of nucleotides 
1849–1863 of the SEMA3E coding sequence in 2 brothers carrying a nucleotide substitution in exon 16 (left side, forward strand; right side, reverse strand; the 
positions of the C>T and corresponding G>A change are indicated with asterisks). (C) Diagram of the SEMA3E functional domains: SEMA, PSI (plexin/sema-
phorin/integrin), Ig (Ig-like, C2-type), and basic domains; their position and the position of the mutated amino acid residue within the protein sequence are indi-
cated. (D) Alignment of partial protein sequences of vertebrate SEMA3E orthologs shows that the R619 residue is evolutionarily conserved in mammals (red), 
but not in chick or zebrafish (green). (E) Genomic evolutionary rate profiling of sequence constraint for the SEMA3E mutation in the 2 KS brothers using GERP++ 
analysis provided an RS score of 5.54, which is close to the maximum score of 6.18 for complete conservation across all mammalian species. (F) Computational 
models of a dimer of the Ig domain of WT and mutant SEMA3E. The model is based on the Robetta algorithm for comparative protein structure prediction. The 
highest-scoring dimer model is shown. The R619 residue and the R619C substitution are indicated by white arrowheads. (G) Schematic drawing illustrating the 
protein interaction between SEMA3E and PLXND1, including its structural domains — the SEMA and PSI domains, similar to those of SEMA3E — as well as the 
IPT (Ig-like, plexin, transcription factor) domains and the serine/threonine protein kinase catalytic domains 1 and 2 (SP1 and SP2).
Table 1. Chromosome position, nucleotide substitution, amino acid substitution, and bioinformatic predictions of the identified 
SEMA3E and CHD7 missense mutations
Chr Position Nt sub AA sub PolyPhen-2 SIFT MutationTaster
7 830114630 G>A R619C Possibly damaging Deleterious Disease causing
8 61735160 T>G F1019C Possibly damaging Deleterious Disease causing
AA sub, amino acid substitution; Chr, chromosome; Nt sub, nucleotide substitution. PolyPhen-2: http://genetics.bwh.harvard.edu/pph2/; SIFT: http://sift.
jcvi.org/; MutationTaster: http://www.mutationtaster.org/.
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Figure 2. SEMA3E promotes GnRH neuron survival via PLXND1 and PI3 kinase activation. (A and B) SEMA3E protects GT1-7 but not GN11 cells from death induced 
by serum starvation. Serum-starved GN11 (top row) and GT1-7 (bottom row) cells were treated with serum or SEMA3E. Dying cells were visualized by PI staining in 
the presence of Hoechst nuclear counterstain (A) to determine the proportion of PI-positive cells relative to all Hoechst-stained cells, shown as the mean ± SEM; 
n = 3; **P < 0.01 and ***P < 0.001 by 1-way ANOVA (B). (C and D) Blocking PLXND1 abolished SEMA3E-mediated neuroprotection of GT1-7 cells. Immunofluores-
cence staining with PLXND1 antibody (αPLXND1) showed that GT1-7 cells expressed PLXND1 (left panel, C). PI and Hoechst staining showed that αPLXND1, but not 
control IgG, inhibited SEMA3E-mediated neuroprotection in GT1-7 cells (right 2 panels, C). Proportion of PI-positive cells in all Hoechst-stained cells (D), shown as 
the mean ± SEM; n = 3; **P < 0.01 by 1-way ANOVA. (E and F) Blocking PI3K abolished SEMA3E-mediated neuroprotection of GT1-7 cells. PI and Hoechst staining 
showed that LY294 did not affect cell death under control conditions (left 2 panels, E), but inhibited SEMA3E-mediated neuroprotection in GT1-7 cells (right 2 pan-
els, E). Proportion of PI-positive cells in all Hoechst-stained cells (F), shown as the mean ± SEM. n = 3; **P < 0.001 by 1-way ANOVA. (G and H) SEMA3E promoted 
PI3K-dependent AKT phosphorylation in GT1-7 neurons. Immunoblotting shows increased levels of phosphorylated AKT (p-AKT) (Ser473) relative to total AKT in 
serum-starved GT1-7 cells treated with SEMA3E, and LY294 abolished SEMA3E-induced AKT phosphorylation. n = 3; **P < 0.01 by Student’s t test. Scale bars:  
10 μm (left panel, C); 25 μm (all other panels). The red line in H indicates the p-AKT/AKT ratio in untreated serum-starved GT1-7 cells, which was set to 1.
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substitution subtly alters the domain conformation of the SEMA3E 
dimer and places the novel cysteine residues in close apposition 
(Figure 1F). The mutation does not reside in a domain predicted to 
mediate binding of SEMA3E to its receptor PLXND1 (Figure 1G). 
Because the specific role of the SEMA3E_Ig domain and the impact 
of the p.R619C mutation on its function is unknown, we compared 
the activity of the wild-type (WT) and mutant recombinant protein 
in tissue culture studies and used mouse genetic tools to examine 
the requirement for SEMA3E in the GnRH neuron system.
SEMA3E signals through PLXND1 in GnRH neurons to promote 
their survival by activating PI3K signaling. To understand how the 
SEMA3E p.R619C mutation contributes to KS, we defined the cel-
lular and biochemical mechanisms through which SEMA3E nor-
mally affects GnRH neurons. For these experiments, we used GN11 
and GT1-7 cells as established models of immature migrating and 
maturing hypothalamic GnRH neurons, respectively (19). Prior work 
had already validated these neuronal cells as useful tools to identify 
molecular pathways involved in GnRH neuron development and 
adult physiology, because they overcome the difficulty in isolating 
primary GnRH neurons in sufficient quantities for biochemical and 
cell biological assays due to their low numbers and scattered distribu-
tion throughout the nose and brain (5, 20–22). We first asked whether 
SEMA3E affected GN11 neuron migration in a Transwell assay previ-
ously used to identify guidance cues for GnRH neurons (23, 24), but 
did not observe any effect (mean number of migrated cells/mm2 ± 
SEM: control, 711 ± 21.5 vs. SEMA3E, 678 ± 15.4; P > 0.05). Because 
SEMA3E promotes cancer cell survival (25), we next asked whether 
it is neuro protective for GN11 cells, which were previously shown to 
use VEGF as a survival signal (21). However, SEMA3E was unable to 
protect GN11 neurons from death; thus, 40% of cells were propid-
ium iodide (PI) positive after serum withdrawal, whereby the rein-
troduction of serum, but not recombinant SEMA3E, for the final 12 
hours of the assay suppressed cell death (Figure 2, A and B; propor-
tion of PI+ cells, mean ± SEM: GN11: DMEM, 41.3% ± 1.3% vs. 10% 
Results
A point mutation in the SEMA3E gene in 2 brothers with KS. By perform-
ing exome sequencing of patients with KS, we identified 2 male sib-
lings (Figure 1A) with a heterozygous substitution of nucleotide 1855 
in the SEMA3E coding sequence (ENST00000307792.3:c.1855C>T) 
(Figure 1B). The brothers had been diagnosed at ages 15 and 17, 
respectively, with anosmia (<10th percentile on a standardized smell 
identification test), prepubertal testes (<2 ml; normally >20 ml), and 
GnRH deficiency (revealed by measuring the levels of the gonado-
tropin LH, which were 1.0 IU/l plasma, and are normally >1.5 IU/l) 
in the setting of hypogonadal testosterone levels (3.5 nmol/l plasma; 
normally 10–50 nmol/l). The mutation was not present in the 1000 
Genomes database and occurred with a very low minor allele fre-
quency in the NHLBI GO Exome Sequencing Project (ESP) database 
in European ancestry samples (0.0004%). The c.1855C>T mutation 
substitutes a charged arginine residue with a neutral but potentially 
disulfide-bondable cysteine residue (p.R619C) and is predicted to 
be deleterious, possibly damaging, and disease causing according 
to the SIFT (14), PolyPhen-2 (15), and MutationTaster (16) bioin-
formatic tools, respectively (Table 1). The R619C mutation resides 
in the extracellular, C-terminal_Ig-like_C2-type domain of SEMA3E 
(Figure 1C) and affects an arginine residue that is highly conserved 
between mammals, but not lower vertebrate species (Figure 1D). 
Genomic evolutionary rate profiling (GERP++) of a large collection 
of mammalian species provided a rejected substitution (RS) score 
that is close to the maximum estimated RS score (17), consistent 
with strong evolutionary constraint against the p.R619C mutation in 
mammals (Figure 1E).
Because the precise structure of the SEMA3E_Ig domain has 
not yet been determined through crystallography, we predicted its 
structure by using the Robetta algorithm (18) to align it with the 
corresponding domains from SEMA3A and other similar entries in 
the Research Collaboratory for Structural Bioinformatics (RSCB) 
Protein Data Bank (PDB). This analysis suggested that the R619C 
Figure 3. KDR is important for 
SEMA3E-induced GnRH neuron sur-
vival in vitro. (A) Expression of KDR in 
GT1-7 cells. RT-PCR analysis revealed 
expression of Plxnd1 in GN11 cells 
and, at higher levels, in GT1-7 cells, 
while Kdr was detectably expressed 
only in GT1-7 cells; Gapdh served as 
a loading control. (B–D) Loss of KDR 
function impaired the SEMA3E-medi-
ated neuroprotection of GT1-7 cells. 
Quantification of cell death in serum-
starved GT1-7 cultures, expressed as 
a percentage of PI-positive cells in all 
cells, which were identified by Hoechst 
staining (B; n = 3; **P < 0.01 by 1-way 
ANOVA), and representative examples 
of stained cultures treated with con-
trol IgG in the absence of neurotrophic 
factors (C) or in the presence of FBS or 
SEMA3E with control IgG or αKDR (D). 
Scale bar: 25 μm in C. 
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34.4% ± 6.4%; P < 0.01, SEMA3E + IgG vs. DMEM or SEMA3E + 
PLXND1). Excluding unspecific effects of the antibody on cell sur-
vival, we observed that blocking PLXND1 function did not affect 
GN11 cells, which use VEGF (21), but not SEMA3E, for survival 
signaling (proportion of PI+ cells, mean ± SEM: DMEM, 38.9% ± 
11.2%; SEMA3E + IgG, 41.1% ± 9.5%; SEMA3E + αPLXND1, 38.9% 
± 7.4%). Together, these findings support the idea that SEMA3E 
promotes the survival of maturing hypothalamic, but not imma-
ture, GnRH neurons in a PLXND1-dependent fashion.
Activation of PI3K and its effector AKT plays a key role in 
survival signaling in many cell types, including neurons (27). In 
agreement with this, treatment with the PI3K inhibitor LY294 
prevented the SEMA3E-mediated protection of GT1-7 cells after 
serum withdrawal (Figure 2, E and F; DMSO, 42.6% ± 2.6%; 
LY294, 43.9% ± 3.3%; SEMA3E + DMSO, 17.9% ± 3.1%; SEMA3E + 
LY194, 45.1% ± 4.6; P < 0.001, SEMA3E + DMSO vs. DMSO) and 
abrogated AKT activation upon SEMA3E stimulation (Figure 2, G 
and H; relative AKT activation at 15 min: SEMA3E, 2.209 ± 0.3 and 
SEMA3E + LY294, 0.19 ± 0.05).
FBS, 8.2% ± 0.4%, P < 0.01; DMEM vs. SEMA3E, 38.9% ± 2.2%, 
P > 0.05). In contrast, cell death of GT1-7 cells, a model of maturing 
GnRH neurons, was dramatically reduced by SEMA3E; thus, 40% of 
cells were PI positive after serum withdrawal, but serum or recombi-
nant SEMA3E for the final 12 hours suppressed cell death (Figure 2, 
A and B; proportion of PI+ cells, mean ± SEM: GT1-7: DMEM, 40.1% 
± 0.9%; 10% FBS, 1.6% ± 0.8%; SEMA3E, 3.6% ± 2.2%; P < 0.001, 
DMEM vs. 10% FBS or SEMA3E). These observations predict a sur-
vival function for SEMA3E in hypothalamic GnRH neurons.
Because SEMA3E signals through PLXND1, we examined 
whether PLXND1 mediated SEMA3E-dependent neuroprotec-
tion of GT1-7 cells. Immunofluorescence staining with a PLXND1 
antibody that fails to stain Plxnd1-null mouse tissue (see mouse-
KO analysis below) showed that GT1-7 cells expressed PLXND1 
(Figure 2C). Because this antibody can block PLXND1 function 
(26), we also used it to treat GT1-7 cells and found that it abolished 
the protective effect of SEMA3E after serum withdrawal (Figure 
2, C and D; proportion of PI+ cells, mean ± SEM: DMEM, 39.8% 
± 5.7%; SEMA3E + IgG, 14.3% ± 9.1%; SEMA3E + αPLXND1, 
Figure 4. The SEMA3ER619C mutation fails to rescue GT1-7 neuron survival. (A and B) Generation of WT and mutant SEMA3E AP fusion proteins. COS-7 
cells were transfected with a control expression vector or vectors encoding AP fused to human SEMA3E or mutant SEMA3ER619C. Cells were immuno-
labeled (A) or immunoblotted (B) with an antibody against SEMA3E. Cells and conditioned media contained a band of approximately 180 kDa, composed 
of the 95-kDa hSEMA3E and 85-kDa AP fragments. Tubulin was used as a loading control. (C) AP-SEMA3E bound WT, but not Plxnd1-null, tissue. Sagittal 
sections of E14.5 mouse cerebral cortex of the indicated genotypes were incubated with AP-SEMA3E. Note that SEMA3E bound blood vessels in WT, but 
not in Plxnd1-null, tissue. (D) AP-SEMA3E binding to GnRH neurons in vitro. The incubation of GT1-7 cells with COS cell–conditioned DMEM containing AP 
ligands demonstrated similar binding of WT AP-SEMA3E and mutant AP-SEMA3ER619C to GT1-7 cells, while AP alone did not bind the cells. (E) SEMA3ER619C 
was not neuroprotective for GT1-7 cells. PI and Hoechst staining shows that WT SEMA3E, but not SEMA3ER619C, mediated neuroprotection of serum-
starved GT1-7 cells. The percentage of PI-positive cells relative to Hoechst-stained cells is shown as the mean ± SEM. n = 3; ***P < 0.001 by 1-way ANOVA. 
(F) The SEMA3ER619C mutation impaired PI3K-dependent AKT phosphorylation. Immunoblotting and graph quantitation show AKT (Ser473) phosphory-
lation relative to total AKT in serum-starved GT1-7 cells treated for 15 minutes with WT SEMA3E or SEMA3ER619C. n = 3; ***P < 0.001 by Student’s t test. 
Scale bars: 50 μm (A), 150 μm (C), 20 μm (D), 100 μm (E).
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The PLXND1 coreceptor KDR promotes SEMA3E-mediated 
GnRH neuron survival. To investigate why GN11 cells were not pro-
tected from cell death by SEMA3E like GT1-7 cells, we compared 
their expression of PLXND1 and the PLXND1 coreceptor KDR, 
also known as FLK1 or VEGFR2, because KDR was shown to be 
essential for PI3K activation during axonal growth of subicular 
neurons (11). Reverse transcriptase PCR (RT-PCR) analysis sug-
gested that GN11 cells express PLXND1, although it was present 
at lower levels than in GT1-7 cells (Figure 3A). Interestingly, we 
detected KDR expression in GT1-7 (Figure 3A). In contrast, KDR 
was not expressed in GN11 cells (Figure 3A), which instead use 
NRP1 as a survival receptor (21). To test whether KDR was required 
for SEMA3E-mediated survival signaling in GT1-7 cells, we used a 
function-blocking antibody for KDR (10, 21). While treatment of 
serum-starved cells with control IgG did not affect the survival 
of GT1-7 cells, the SEMA3E-mediated protection of GT1-7 cells 
was abrogated by anti-KDR (Figure 3, B–D; DMEM + IgG, 47% 
± 1.9%; 10% FBS + IgG, 4.3% ± 1.1%; 10% FBS + αKDR, 8.8% ± 
1.7%; SEMA3E + IgG, 14.1% ± 1.3%; SEMA3E + αKDR, 48.7% ± 
2.3%). Taken together, these observations suggest that SEMA3E 
signals through PLXND1 in a KDR-dependent fashion to promote 
PI3 kinase activation in maturing GnRH neurons.
SEMA3E, but not SEMA3ER619C, promotes GnRH neuron survival 
by activating PI3K signaling. To investigate whether the SEMA3ER619C 
mutation impaired GnRH neuron survival by impairing AKT acti-
vation, we engineered expression constructs encoding human 
WT SEMA3E or SEMA3ER619C protein and expressed them in COS 
cells to generate recombinant protein for tissue culture studies. 
Immuno staining and immunoblotting established that both pro-
teins were expressed and secreted effectively (Figure 4, A and 
B). Because we engineered recombinant SEMA3E as an alkaline 
phosphatase- conjugated ligand (AP-SEMA3E), we were also able 
to use it for binding assays. Binding of AP-SEMA3E to WT, but not 
to Plxnd1-null, mouse tissue established specificity of the AP-SE-
MA3E ligand (Figure 4C). Ligand-binding assays demonstrated 
that both WT SEMA3E and SEMA3ER619C bound GT1-7 cells (Fig-
ure 4D). Even though mutant SEMA3E retained its ability to bind 
GT1-7 cells, it failed to protect them from death induced by serum 
starvation (Figure 4E; control, 38.3% ± 0.9% vs. WT SEMA3E, 
13.2% ± 3.5%, P < 0.001; control vs. SEMA3ER619C, 36.0% ± 2.4%; 
P > 0.5). Moreover, SEMA3ER619C was ineffective in AKT activation in 
serum-starved GT1-7 cells (Figure 4F). Taken together, these observa-
tions suggest that SEMA3E-mediated survival signaling in maturing 
GnRH neurons is compromised by the SEMA3E p.R619C mutation.
PLXND1 expression during mouse GnRH neuron development. 
The tissue culture studies above suggested that SEMA3E signaling 
is essential to promote the survival of maturing GnRH neurons, 
i.e., GnRH neurons at late stages of embryonic development. To 
Figure 5. PLXND1 is expressed during 
GnRH neuron migration in the mouse. 
(A) Schematic representation of an 
embryonic mouse head to illustrate 
the migration of GnRH neurons (green 
dots) from the olfactory (OE) and VNO 
epithelia (blue) along OLF and VN axons 
(purple) through the nasal compart-
ment (NC) into the forebrain (FB). (B–H) 
Sagittal and coronal sections of mouse 
heads at the indicated developmental 
stages, immunolabeled for GnRH and 
PLXND1; nuclei were counterstained 
with DAPI. Higher-magnification images 
of the areas indicated with dotted 
squares in B are shown in panels C and 
D, and for E and G in F and H, respec-
tively. Adjacent to each panel in B–H, 
the corresponding single channels for 
PLXND1 are shown in grayscale. In C, 
clear arrows indicate PLXND1-positive, 
GnRH-negative cells, and clear arrow-
heads indicate examples of GnRH-pos-
itive, PLXND1-negative cells in the OE. 
Solid arrows in D indicate GnRH neurons 
with low levels of PLXND1 in associa-
tion with OLF axons with high levels of 
PLXND1. In F, clear arrowheads indicate 
PLXND1-negative GnRH neurons (their 
position is indicated with an asterisk). 
In H, PLXND1-positive GnRH neurons in 
the MPOA and their neurites are indi-
cated with straight and wavy arrows, 
respectively. Scale bars: 150 μm (B, E, 
and G); 50 μm (C, D, and F); 25 μm (H).
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determine the expression pattern of PLXND1 and its functional 
requirement for GnRH neuron development, we used the mouse 
as a model organism. Most mouse GnRH neurons arise between 
E10.5 and E12.5 in the nasal placode that also gives rise to the 
olfactory epithelium (OE) and vomeronasal organ (VNO) (4). 
Newly born GnRH neurons leave the placode by migrating along 
olfactory (OLF) and vomeronasal (VN) axons toward the fore-
brain, which they enter by following along the caudal branch of 
the VN/terminal nerve (Figure 5A). Immunofluorescence labeling 
of sagittal sections identified abundant PLXND1 expression in the 
E12.5 head (Figure 5B). In particular, PLXND1 localized to nasal 
axons and blood vessels as well as to the OE and VNO epithelia 
(Figure 5C). However, most GnRH-positive cells (corresponding 
to GnRH neurons) within the OE and VNO or elsewhere in the 
nose appeared only faintly positive or negative for PLXND1 (Fig-
ure 5, C and D). Immunofluorescence labeling of coronal sections 
through E14.5 heads showed a similar pattern of PLXND1 expres-
sion in the OE and VNO, but absent or faint expression on GnRH 
neurons in the nose (Figure 5, E and F). Although only weakly 
positive for PLXND1 while migrating in the nose, GnRH neurons 
Figure 6. PLXND1 is dispensable for axonal and vascular patterning in the embryonic mouse nose. (A) PLXND1 expression in E12.5 mouse nose. Sagittal 
sections of E12.5 WT heads, immunolabeled for PLXND1 and the OLF/VN axonal marker peripherin (top panels) or the vascular marker IB4 (bottom panels); 
sections were counterstained with DAPI. Higher-magnification images of the areas indicated with dotted squares are shown in the adjacent panels. The 
clear arrow indicates a PLXND1-positive axon and the solid arrow a PLXND1-positive blood vessel. (B) PLXND1 expression in E14.5 mouse nose and brain. 
Coronal sections of E14.5 WT nose (top panels) and MPOA (bottom panels), immunolabeled for PLXND1 and peripherin; sections were counterstained with 
DAPI. Higher-magnification images of the areas indicated by dotted boxes are shown in the adjacent panels. PLXND1 expression in axons in the nose and 
OLF bulbs (OB) is indicated with arrowheads. Note PLXND1 expression by GnRH neurons in the MPOA (clear arrow), but not by the caudal branch of the VN 
nerve (clear arrowhead). 3v, third ventricle.  (C and D) Normal nasal axon and nasal/brain blood vessel patterning in Plxnd1-null mutants. Coronal sections 
of E14.5 mouse heads of the indicated genotypes at the level of the nose (top panels) and MPOA (bottom panels) were immunolabeled for peripherin and 
counterstained with DAPI (C) or labeled with the blood vessel marker IB4 (D). Dotted lines indicate forebrain boundaries. Scale bars: 150 μm (A–D), 50 μm 
(higher-magnification images of boxed areas in A and B).
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PLXND1-null mutants show normal axonal and blood ves-
sel patterning in the nose and forebrain. Mice lacking neuropilin 
signaling show ectopic GnRH neuron migration along mispat-
terned axons in the nose and an ensuing accumulation of ecto-
pic GnRH neurons outside the brain (5). Because PLXND1 was 
present on nasal axons at E12.5 (Figure 6A) and E14.5 (Figure 
6B), we examined whether nasal axon tracts were also defective 
in Plxnd1- null mice, but found no obvious abnormalities (Figure 
6C). In addition, the caudal branch of the VN/terminal nerve 
that guides GnRH neurons into the forebrain appeared PLXND1 
negative (Figure 6B) and projected normally in Plxnd1-null mice 
(Figure 6C), excluding a role for PLXND1 in directing GnRH 
neuron migration into the brain. Because PLXND1 was previ-
ously implicated in trunk and retinal vascular patterning (9, 10) 
and is expressed by blood vessels in both the nose and forebrain 
that had entered the forebrain began to express PLXND1; more-
over, GnRH neurons in the medial preoptic area (MPOA), where 
most hypothalamic GnRH neurons eventually reside, expressed 
PLXND1 strongly on both their cell bodies and axons (Figure 5, G 
and H; 81.6% ± 7.9% of GnRH+ cells were also PLXND1+). These 
observations are consistent with a requirement for SEMA3E sig-
naling through PLXND1 in developing GnRH neurons after they 
have entered the brain, consistent with the in vitro analysis, which 
suggested a role for SEMA3E in GnRH neurons at an advanced 
stage of differentiation. In addition, the expression pattern may 
indicate possible roles for PLXND1 in vascular and OLF devel-
opment. We therefore examined whether disrupted vascular pat-
terning, abnormal OLF axon guidance, and/or cell-autonomous 
defects in GnRH neurons might contribute to the loss of GnRH 
neurons in PLXND1-null mice.
Figure 7. Reduced GnRH neuron numbers and increased apoptosis correlate in the Plxnd1-null MPOA. (A and B) PLXND1 loss caused GnRH neuron loss after 
the forebrain. Sagittal sections of E14.5 mouse heads were immunolabeled for GnRH, revealing fewer GnRH neurons in mutant compared with WT heads (A). 
Dotted lines indicate the boundary between the nose and forebrain. White dotted squares indicate regions shown at higher magnification in the adjacent 
panels. (B) Quantitation of GnRH neuron distribution shows that GnRH neuron loss was only significant in the mutant forebrain, but not the nose (n = 3 
each; **P < 0.01, Student’s t test). (C and D) PLXND1 loss caused GnRH neuron loss in the MPOA. (C) Coronal sections of E17.5 MPOA were immuno labeled for 
GnRH, revealing fewer GnRH neurons in the mutant mice than in the WT mice. (D) Quantitation confirmed a significant reduction of GnRH neuron numbers 
in PLXND1- deficient compared with WT MPOA (n = 3 each; **P < 0.01, Student’s t test). (E and F) PLXND1 loss increased apoptosis in the MPOA. (E) Adjacent 
coronal sections of E14.5 MPOA were immunolabeled for GnRH together with PLXND1 or activated caspase-3, revealing apoptotic cells in areas containing 
GnRH neurons (indicated with solid arrowheads). Higher-magnification images of areas indicated with dotted squares are shown in the adjacent panels.  
(F) Quantitation shows increased cell death in the MPOA of Plxnd1-null versus WT mice (n = 3 each; **P < 0.01, Student’s t test). (G) PLXND1 loss caused 
GnRH neuron apoptosis. Gnrh ISH of coronal sections from E14.5 MPOA followed by immunolabeling for activated caspase-3 revealed apoptotic GnRH neurons 
(indicated with solid arrowheads). Scale bars: 150 μm (A and E), 50 μm (C and higher-magnification images of boxed areas in E), 45 μm (G).
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sparse in littermate mutants, and residual neurons appeared col-
lapsed (Figure 7, C and D; Plxnd1+/+, 933 ± 21 vs. Plxnd1–/–, 486 ± 
26, P < 0.001; heterozygous mice had a normal number of GnRH 
neurons: Plxnd1+/–, 979 ± 18; n = 3). Together, these findings sug-
gest that PLXND1 is specifically required to maintain a normal 
number of GnRH neurons after they have entered the brain. 
These results also agree with the observed PLXND1 upregula-
tion in GnRH neurons in the brain relative to the nose and the 
responsiveness of mature GT1-7, but not immature GN11, cells to 
SEMA3E-induced survival signaling in vitro.
We next examined whether PLXND1 is required for the sur-
vival of GnRH neurons in the developing brain. For this analysis, we 
labeled adjacent coronal sections through the MPOA, where most 
GnRH neurons reside after E14.5, with antibodies against GnRH 
and PLXND1 or activated caspase-3, a marker for cells committed 
to undergo apoptosis (Figure 7E). We identified many GnRH neu-
rons, but few apoptotic cells, in the WT MPOA (Figure 7E, upper 
panels); in contrast, GnRH neurons were sparse and apoptotic cells 
prominent in the mutant MPOA (Figure 7E, right lower 2 panels). 
This experiment confirmed the specificity of the PLXND1 antibody 
used, as it did not label mutant tissue (Figure 7E, left lower 2 pan-
els). Quantitation confirmed a significant increase in the number 
of apoptotic cells in the mutant MPOA at E14.5 (Plxnd1+/+, 8 ± 0.5 
vs. Plxnd1–/–, 21 ± 1.8, P < 0.01) (Figure 7F). Because we could not 
identify suitably compatible antibodies to detect GnRH, PLXND1, 
and activated caspase-3 by triple immunolabeling, we instead com-
bined Gnrh ISH with immunostaining for activated caspase-3 to 
demonstrate directly that GnRH neurons undergo apoptosis when 
they have reached the MPOA (arrowheads, Figure 7G). Finally, we 
combined immunofluorescence for GnRH with TUNEL staining 
(28) at E14.5 to identify GnRH neurons in the terminal stages of 
apoptosis (Supplemental Figure 1; supplemental material available 
online with this article; doi:10.1172/JCI78448DS1). Together, these 
during GnRH neuron migration (Figure 5C and Figure 6A), we 
next examined whether PLXND1-null mutants have insuffi-
cient tissue vascularization that could indirectly affect GnRH 
neuron development. However, fluorescence staining of E14.5 
head sections with the vascular marker IB4 did not identify any 
obvious differences in blood vessel organization in the nose or 
brain between mutants and their littermate controls (Figure 6D). 
Taken together, these data are consistent with a cell-autonomous 
role for PLXND1 signaling in GnRH neurons, rather than indi-
rect effects of PLXND1-dependent OLF/VN nerves or blood ves-
sels on GnRH neuron development.
PLXND1 loss impairs GnRH neuron survival in the developing 
mouse brain. Because we had observed that PLXND1 promoted 
SEMA3E-mediated survival signaling in a GnRH neuron tissue 
culture model and found high expression of PLXND1 in forebrain 
GnRH neurons in situ, we next asked whether Plxnd1-null mice (9) 
lacked GnRH neurons. IHC for GnRH of sagittal sections followed 
by quantitation of all GnRH-positive cells in each head demon-
strated a significant reduction in the number of GnRH neurons in 
mutants compared with WT mouse heads at E14.5 (Figure 7, A and 
B; Plxnd1+/+, 1,322 ± 34 vs. Plxnd1–/–, 1,051 ± 43; P < 0.01). Because 
GnRH neurons at E14.5 reside in both the nose and forebrain, we 
next determined the relative amount of neurons in both compart-
ments. Whereas the number of GnRH-positive cells was similar 
in the nose of both genotypes, their numbers were significantly 
reduced in the forebrain of mutants compared with WT (Figure 
7B; nose: Plxnd1+/+, 861 ± 13 vs. Plxnd1–/–, 867 ± 31, P > 0.05; fore-
brain: Plxnd1+/+, 469 ± 51 vs. Plxnd1–/–, 191 ± 29, P < 0.01).
To exclude that the reduced number of GnRH neurons in the 
mutant brain at E14.5 was not caused by a developmental delay, 
we examined the MPOA of Plxnd1-null mutants and their litter-
mates during late embryogenesis. While many GnRH neurons 
were present in the WT MPOA at E17.5, GnRH neurons were 
Figure 8. KDR deficiency decreases GnRH neuron numbers in the brain. (A) GnRH neurons expressed KDR in the brain. Coronal sections of E17.5 mouse 
MPOA of the indicated genotypes were immunolabeled for GnRH and KDR.Higher-magnification images of the areas indicated by dotted boxes and corre-
sponding single channels for KDR are shown adjacent to each panel. White arrowheads indicate examples of GnRH-positive cells; red arrowheads indicate 
KDR staining in the same cells in the single-channel images. Clear red arrowheads indicate GnRH-positive cells with KDR knockdown. Small white and red 
arrows indicate KDR-positive blood vessels. (B and C) Reduced number of GnRH neurons in the brain of mice lacking KDR in neurons. Coronal sections of 
E17.5 mouse MPOA from the indicated genotypes were immunolabeled for GnRH (B) and the number of GnRH neurons quantitated (C) (n = 3 each;  
**P < 0.01, Student’s t test). Scale bars: 150 μm and 50 μm (low- and high-magnification images in A, respectively), 50 μm (B).
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strated a significantly reduced number of GnRH neurons in Kdrfl/– 
Nes-Cre mutants compared with that in control littermates (Figure 
8C; Kdrfl/+, 910 ± 30 vs. Kdrfl/– Nes-Cre, 650 ± 18; P < 0.01). These 
observations agree with the finding that GT1-7 cells require KDR 
for SEMA3E-mediated survival signaling via PLXND1 in vitro.
Loss of the PLXND1 ligand SEMA3E decreases GnRH neuron 
numbers in the brain. Consistent with a role for SEMA3E survival sig-
naling in GnRH neurons in the MPOA, SEMA3E localized to PLX-
ND1-positive GnRH neurons and was present in their environment 
(Figure 9A). IHC staining, followed by counting of all GnRH-posi-
tive cells in each head, demonstrated a significant reduction in the 
number of GnRH neurons in Sema3e-null mutants compared with 
WT littermates at E14.5 (Figure 9, B and C; Sema3e+/+, 1,400 ± 47 
vs. Sema3e–/–, 922 ± 106; P < 0.01). Moreover, residual neurons in 
the MPOA at E14.5 appeared collapsed (Figure 9B), and neuron 
loss was pronounced in the forebrain but not the nose (Figure 9D; 
nose: Sema3e+/+, 905 ± 36 vs. Sema3e–/–, 857 ± 75, P > 0.05; fore-
brain: Sema3e+/+, 486 ± 12 vs. Sema3e–/–, 214 ± 14, P < 0.01). The 
phenotypic similarity of mice lacking SEMA3E with that of mice 
experiments show that loss of PLXND1 signaling compromises 
GnRH neuron survival in the developing brain.
Loss of the PLXND1 coreceptor KDR decreases GnRH neuron 
numbers in the brain. Because our in vitro experiments suggested 
that SEMA3E-mediated survival signaling through PLXND1 
was dependent on the PLXND1 coreceptor FLK1, we examined 
whether GnRH neurons in the MPOA expressed KDR and whether 
KDR was required for their survival. We observed that GnRH neu-
rons in the E17.5 MPOA of control mice expressed KDR (Figure 8A, 
top panels). In contrast, Kdrfl/– Nes-Cre–mutant mice lacking KDR 
in the neural lineage (11) showed only faint expression of KDR in 
GnRH neurons (Figure 8A). Importantly, blood vessels retained 
KDR immunoreactivity in the mutants, demonstrating specificity 
of the neural KO (Figure 8A, bottom panels). This experiment also 
showed that fewer GnRH neurons were present in the E17.5 MPOA 
of mutants compared with that seen in controls (Figure 8A, bottom 
panels). We therefore immunostained sections through the entire 
MPOA of E17.5 mutants and controls and then quantified the num-
ber of GnRH neurons (Figure 8, B and C). This analysis demon-
Figure 9. SEMA3E deficiency reduces GnRH neuron numbers, projection to the ME, and testes size. (A) SEMA3E in the MPOA. Adjacent coronal sections 
of E14.5 mouse MPOA, immunolabeled for GnRH and PLXND1 or SEMA3E; the SEMA3A single channel is shown adjacent to the triple label. Arrowheads 
indicate examples of PLXND1- and GnRH-positive neurons stained for SEMA3E, consistent with SEMA3E binding to PLXND1. (B–D) SEMA3E loss reduced 
GnRH neuron numbers. (B) Coronal sections of E14.5 MPOA were immunolabeled to identify GnRH neurons; Δ denotes neuron deficiency in mutants com-
pared with controls; arrowheads indicate examples of GnRH neurons with a normal, elongated morphology; black arrows indicate rounded GnRH neurons 
in the mutants. (C) Quantitation revealed a significant reduction in GnRH neuron numbers in Sema3e mutants compared with WT littermates. n = 3;  
**P < 0.01 by Student’s t test. (D) Quantitation revealed a significant reduction of GnRH neuron numbers in Sema3e mutant relative to WT forebrain, but 
normal numbers in the nose. n = 3; **P < 0.01 by Student’s t test. (E) Loss of SEMA3E or neural PLXND1 reduced GnRH neuron projections to the ME. Cor-
onal sections of adult hypothalamus were immunostained to identify GnRH-positive axons (green) projecting to the ME (counterstained with DAPI, blue); 
innervation was poor in mutants compared with that in WT (indicated by Δ). (F) Loss of SEMA3E or neural PLXND1 reduced testes size. Testes pairs from 
adult littermate males were photographed side by side to demonstrate the reduced size of testes in SEMA3E-null and neuron-specific PLXND1 mutants. 
Scale bars: 25 μm (A); 50 μm (B); 50 μm (E); 300 μm (F).
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which is caused by endothelial cell defects in the cardiac outflow 
tract (9, 31). Similar to Sema3e-null mutants, the ME of Plxnd1fl/fl 
Nes-Cre adult males was poorly innervated by GnRH-positive 
axons (Figure 9E; GnRH pixel intensity reduction in ME neu-
rites in mutants relative to that seen in WT littermates: Sema3e–/–, 
36% ± 0.8%; Plxnd1fl/fl Nes-Cre, 49% ± 1.6%). This experiment 
also provided additional evidence for a cell-autonomous func-
tion of PLXND1 rather than roles for PLXND1-dependent vas-
culature in GnRH neuron survival.
Impaired GnRH neuron innervation of the ME is predicted 
to reduce gonadotropin secretion from the pituitary and thereby 
affect normal sexual development. Consistent with this idea, 
and in agreement with the phenotype of patients carrying the 
lacking PLXND1 or KDR agrees with the idea that SEMA3E serves 
as a ligand for a PLXND1/KDR coreceptor complex to promote the 
survival of GnRH neurons in the developing brain.
Loss of SEMA3E or neuronal PLXND1 decreases innervation of 
the adult median eminence by GnRH neurons and the size of adult 
testes. In adults, GnRH neurons project to the median eminence 
(ME), where they release GnRH into the portal blood vessels 
of the pituitary gland. We observed a markedly reduced num-
ber of GnRH-positive neurites at the ME in adult Sema3e-null 
compared with WT males (Figure 9E). We also examined ME 
innervation in Plxnd1 mutants. For this experiment, we created 
neuron-specific PLXND1-null mice (Plxnd1fl/fl Nes-Cre; refs. 29, 
30) to circumvent the neonatal lethality of full Plxnd1-null mice, 
Figure 10. Genetic interaction of SEMA3E and CHD7 in KS. (A) Pedigree of the 2 brothers affected by KS. A heterozygous p.F1019C mutation in CHD7 is 
present in the brothers with the p.R619C mutation in SEMA3E. Circle denotes female; square denotes male; black square denotes affected male; arrows 
indicate the probands. (B) Identification of the CHD7 mutation. Sequence chromatograms revealed a heterozygous nucleotide substitution (T>G, asterisks) 
in exon 12 of CHD7. (C) The CHD7 mutation affects an evolutionarily conserved amino acid residue. Alignment of partial protein sequences of CHD7 orthologs 
shows that F1019 (red) is evolutionarily conserved. (D) CHD7 domain structure. The position of the mutation is indicated. CD, chromodomain; DEXDc, dead-
like helicase domain with ATP-binding pocket; SANT, histone interaction domain; BRK, Brahma and Kismet domain. (E and F) Genetic interaction of Chd7 
and Plxnd1. Coronal sections of hypothalamus from adult littermate mice of the indicated genotypes, immunostained to identify GnRH-positive axons 
at the ME (E), and the quantitation of GnRH pixel intensity in the immunostained sections (F), show more severely reduced ME innervation in compound 
compared with single mutants. n = 3 each; *P < 0.05 and ***P < 0.001 by 1-way ANOVA. The testes size (E) was correspondingly reduced. Scale bars: 25 μm 
(ME in E), 400 μm (testes in E).
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Chd7+/– males were able to sire offspring suggested that the hete-
rozygous loss of CHD7 function affects the GnRH neuron system 
at a subclinical level. Strikingly, compound heterozygous Plxnd1+/– 
Chd7+/– males showed a more pronounced reduction in the intensity 
of GnRH neuron projections at the ME than their Chd7+/– littermates 
with normal PLXND1 levels (Figure 10E, top panels). Similar results 
were also obtained for female mice (Figure 10F; reduced GnRH 
pixel intensity at the mutant ME relative to the WT female ME at 
P14: Chd7+/– Plxnd1+/+, 25.5% ± 3.1%, P < 0.05; CHD7+/– Plxnd1+/–, 
55.2% ± 2.5%, P < 0.001). Consistent with reduced ME innervation 
and also with the phenotype of the 2 brothers carrying the SEMA3E 
and CHD7 mutations, the testes of adult Plxnd1+/– Chd7+/– compound 
heterozygous males were smaller than those of WT and Chd7+/– litt-
ermate males (Figure 10E, bottom panels). Together, these observa-
tions suggest that CHD7 and PLXND1 interact genetically to enable 
formation of the GnRH neuron system.
Discussion
KS is a rare genetic condition that impairs puberty and human 
reproduction and can be treated if diagnosed early. Here, we have 
combined exome sequencing of patients with bioinformatics anal-
ysis, tissue culture experiments, and animal models to identify 
SEMA3E as a novel KS gene that controls GnRH neuron develop-
ment. The heterozygous nature of the SEMA3E mutation we iden-
tified agrees with the current model of oligogenic inheritance of 
various combinations of heterozygous mutations in the SEMA3A, 
FGFR1, NELF, KAL1, PROKR2, and PROK2 genes (7, 32–36). In 
agreement with this finding, the heterozygous SEMA3E mutation 
was accompanied by a heterozygous missense mutation in CHD7 
that was not present in any other exome in the 1000 Genomes and 
ESP databases. Importantly, the presence of the same SEMA3E 
and CHD7 mutations in brothers with a 2-year age difference sug-
gests that both mutations were inherited. However, lack of access 
to parental DNA prevented our ability to investigate whether the 
SEMA3E mutation was inherited through the paternal or maternal 
lineage, and whether the CHD7 mutation was inherited from the 
other parent, as may be predicted from the fertility of the parents, 
but infertility of their children, who combined both mutations. 
Supporting the idea of oligogenic inheritance and an interaction 
of the genes encoding SEMA3 family members and CHD7, two 
KS siblings with a heterozygous missense mutation in CHD7 were 
previously shown to also carry a heterozygous missense mutation 
in SEMA3A (40). Moreover, CHD7 haploinsufficiency affects the 
expression of Sema3a in mice (43).
To validate SEMA3E as a novel KS gene and determine its role 
in the GnRH neuron system, we used in vitro models to demon-
strate the pathogenicity of the R619C mutation and phenotyped 
KO mice lacking Sema3e or its receptor Plxnd1 or coreceptor Kdr. 
These studies identified SEMA3E as a novel neurotrophic factor 
that signals via PLXND1 and KDR to activate prosurvival signal-
ing in GnRH neurons. This function differs significantly from pre-
viously known roles for SEMA3E in modulating the cytoskeleton 
during vascular and axon guidance (44). Moreover, the functional 
importance of SEMA3E for neuron survival is fundamentally dif-
ferent from that of SEMA3A, which is mutated in other KS patients 
(7), but causes the ectopic migration of GnRH neurons along mis-
patterned axons in the nose (5).
SEMA3ER619C mutation, the testes of adult male mice lacking 
SEMA3E or neuronal PLXND1 were smaller than those of WT 
littermates (Figure 9F). On the basis of these findings in genetic 
mouse models and combined with the identification of a SEMA3E 
mutation in 2 brothers with KS and our tissue culture studies with 
recombinant SEMA3E, we conclude that loss of SEMA3E, either 
through genetic deletion or mutation, contributes to the etio-
pathogenesis of inherited GnRH deficiency, including KS.
A heterozygous missense mutation in CHD7 accompanies the R619C 
mutation in SEMA3E in the KS brothers. While the mouse mutants we 
have examined here were bred to homozygosity to define a role for 
SEMA3E in GnRH neuron development, the R619C mutation in 
SEMA3E we identified in the 2 KS brothers was present in a hetero-
zygous pattern. This finding agrees with the commonly observed 
oligogenic inheritance pattern of KS in the human population, 
which is exemplified by various combinations of previously identi-
fied hetero zygous mutations in the SEMA3A, FGFR1, NELF, KAL1, 
PROKR2, and PROK2 genes (7, 32–36). We therefore examined the 
exome sequence of both KS brothers for mutations in all other pre-
viously identified KS genes, but found no such mutations except the 
same missense mutation in the gene encoding the chromodomain 
helicase DNA–binding protein 7 (CHD7) in both brothers (Figure 10, 
A and B). This nucleotide substitution replaced the codon for pheny-
lalanine with a codon for cysteine (p.F1019C) and was not present in 
any other exome in the 1000 Genomes and ESP databases.
CHD7 is a chromatin remodeler that modulates gene tran-
scription during the development of multiple organ systems (37, 
38), and CHD7 mutations are the main cause of CHARGE syn-
drome (coloboma, heart defect, choanal atresia, retardation of 
growth and/or development, genital hypoplasia, ear anomalies) 
(39). However, while CHARGE patients commonly carry severe 
truncating mutations in CHD7, missense mutations in CHD7 are 
more prevalent in KS patients (40). In agreement with these ear-
lier observations, the CHD7 mutation we identified in the brothers 
with KS is a missense mutation that was predicted to be possibly 
damaging, deleterious, or disease causing by PolyPhen-2, SIFT, 
and MutationTaster bioinformatic tools, respectively (Table 1). 
Thus, the F1019C mutation affects an amino acid residue that is 
highly conserved between mammals and lower vertebrate species 
(Figure 10C) and is positioned on the DEAD-like helicase domain 
(DEXDC) that is essential for ATP binding (Figure 10D).
In summary, the coexistence of the same heterozygous mis-
sense mutation in CHD7 mutations in the 2 brothers with a 2-year 
age difference suggests that both mutations were inherited from 
their fertile parents and is consistent with the idea that CHD7 
functions cooperatively with SEMA3E in a genetic pathway essen-
tial for GnRH neuron development.
Genetic interaction of PLXND1 and CHD7 in the GnRH neuron 
system. Because the heterozygous loss of PLXND1 did not impair 
GnRH neuron development (see above), we were able to examine 
the genetic interaction of PLXND1 and CHD7. Thus, we mated 
Plxnd1+/– females with Chd7+/– males (41) and examined the inner-
vation of the ME in single and compound heterozygous mice. We 
found that fewer GnRH-positive neuron fibers projected to the ME 
in the hypothalamus of their Chd7+/– male offspring compared with 
that seen in their WT littermates (Figure 10E, top panels), consis-
tent with previous observations (42). Importantly, the finding that 
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neurons migrating in the nose (21). Together, these observations 
suggest that GnRH neurons change their mechanism of survival 
signaling as they negotiate consecutive anatomical territories dur-
ing their journey from the nasal placodes to the hypothalamus.
A role for PLXND1 in cell survival has recently been demon-
strated in breast cancer cells, in which it acts as a dependence 
receptor that promotes cell death in the absence of the SEMA3E 
ligand. A role for SEMA3E as a rescue ligand to overcome the 
default pathway of receptor-induced death is, however, unlikely 
for GnRH neurons. First, the number of GnRH neurons is similarly 
reduced in mice lacking the PLXND1 receptor or the SEMA3E lig-
and, arguing against a role for PLXND1 in inducing GnRH neuron 
death. Second, we found that SEMA3E promoted GnRH neuron 
survival in vitro in a PLXND1-dependent fashion via PI3K/AKT, 
a conventional survival pathway that inhibits proapoptotic media-
tors such as BAX and BAD in neurons (27).
In conclusion, our study has uncovered a hitherto unknown 
role for SEMA3E as a neurotrophic factor that is essential for 
GnRH neuron development by signaling via PLXND1 to activate 
PI3K. Moreover, we have demonstrated that exome sequencing, 
combined with bioinformatics tools, tissue culture models, and 
the analysis of genetically modified mice, enables the identifica-
tion and functional description of genes involved in GnRH neuron 
development and disease. We therefore anticipate that our study 
will prompt direct SEMA3E mutation screening in KS patients and 
lead to the increased application of exome sequencing for KS gene 
discovery as well as provide a starting point for mechanistic stud-
ies of GnRH neuron development and deficiency.
Methods
DNA sequencing and bioinformatics. Genomic DNA from 174 subjects 
(121 diagnosed with KS/HH, 53 unaffected) was prepared from white 
blood cells using a standard procedure and the exomes sequenced 
with an Illumina HiSeq 2000 platform using the Agilent V5 Exon Cap-
ture kit (Agilent Technologies). Exome sequencing alignment data 
for the 2 brothers affected by KS for SEMA3E, CHD7, and the known 
genes underlying KS/HH are available at the European Nucleotide 
Archive (ENA) (accession number PRJEB8931). The p.R619C muta-
tion in SEMA3E and the p.F1019C mutation in CHD7 were confirmed 
by Sanger sequencing. To calculate evolutionary constraint against 
nucleotide substitution at position c.1855C>T in SEMA3E, we used the 
GERP++ analysis tool.
Mouse strains. To obtain embryos of defined gestational stages, 
mice were mated in the evening, and the morning of vaginal plug 
formation was counted as E0.5. We used mice carrying Plxnd1-null, 
Sema3e-null, or Chd7-null (gift of Peter Scambler, UCL) alleles and 
mice carrying floxed conditional Plxnd1-null or Kdr-null alleles with a 
Nes-Cre transgene (9, 11, 29, 30, 41).
Immunostaining. Formaldehyde-fixed tissue sections and cells 
were incubated with PBS containing 10% normal goat serum and 
0.1% Triton X-100 or, for primary goat antibodies, with serum-free 
protein block (DAKO). The following primary antibodies were used 
for immunostaining: rabbit anti-peripherin (1:500; catalog AB1530; 
Chemicon); rabbit anti-GnRH (1:400; catalog 20075; ImmunoStar); 
rabbit anti-activated caspase-3; goat anti-human/mouse SEMA3E; 
and goat anti-human/mouse PLXND1 and goat anti-mouse KDR 
(1:150; catalogs MAB835, AF3239, AF4160, and AF644, respectively; 
The p.R619C mutation we identified resides in the Ig-like 
C2-type domain that is conserved in all class 3 semaphorins. The 
basic domain of semaphorins enables binding to neuropilins with 
high affinity, and the signature SEMA domain confers specificity 
for neuropilins, which act as plexin coreceptors (45, 46). Instead, 
the Ig-like domain makes only a minor contribution to repulsive 
semaphorin activity in axon guidance (47), and its precise func-
tion has not previously been defined. Interestingly, the p.R619C 
mutation resides near a cysteine that enables dimerization of the 
Ig domain in other class 3 semaphorins (48). Computational mod-
eling based on known crystal structures predicted that the novel 
cysteine residues are closely opposed in the mutant dimer and 
raises the possibility that an abnormal disulfide bridge might form 
and thereby impair structural flexibility. Together with the loss of 
a negative surface charge that may impact intra- or intermolecular 
interactions, this mutation was therefore predicted to compromise 
domain function. In agreement with this, functional assays demon-
strated an essential role for SEMA3E in survival signaling via PI3 
kinase activation that was impaired by the p.R619C mutation.
Notably, the SEMA3E prosurvival pathway we have identified 
is specific to GT1-7 cells, a model of developing GnRH neurons 
in the forebrain, but not GN11 cells, a model of GnRH neurons at 
an earlier stage of development, when they migrate in the nose. 
These observations agree with in vivo data on the role of VEGF/
NRP1 versus SEMA3E/PLXND1/KDR signaling in GnRH neuron 
development. Thus, immature GnRH neurons migrating in the 
embryonic nose express NRP1, and their pool is reduced in mice 
lacking NRP1 or NRP1-binding VEGF (21), but is shown here to 
be unaffected in mice lacking SEMA3E or PLXND1. By contrast, 
we found that GnRH neurons upregulate PLXND1 after forebrain 
entry and during their migration toward the hypothalamus and that 
they depend on SEMA3E/PLXND1 survival signaling at this devel-
opmental stage. This exquisite spatiotemporal specificity in signal-
ing pathways for neurotrophic support appears an ideal adaption 
for neurons that have to negotiate molecularly distinct territories 
when traveling from their birthplace to the site of synaptogenesis.
An intriguing question is why developing GnRH neurons in 
the forebrain respond to SEMA3E with survival signaling rather 
than modulation of the actin cytoskeleton, as observed in endo-
thelial cells of some vascular beds (9) and in axons (12). During 
axon guidance, cell type–specific responses to semaphorins are 
facilitated by coreceptor recruitment. Thus, PLXND1 signals axon 
attraction in neurons that coexpress NRP1, but repulsion in neu-
rons lacking NRP1 (12). Moreover, the presence of KDR is required 
for SEMA3C-induced PI3K activation downstream of PLXND1/
NRP1 signaling for axonal growth in subico-mammillary neu-
rons (11). On the basis of these observations, it appears likely that 
PLXND1 also recruits a coreceptor to activate PI3K in GnRH neu-
rons and initiate the survival response. NRP1 is an unlikely cofactor 
for PLXND1 prosurvival signaling in GnRH neurons, because it is 
downregulated in these neurons after forebrain entry (A. Cariboni 
and C. Ruhrberg, unpublished observations). In contrast, VEGFR2 
was expressed by GnRH neurons in the MPOA and was essential 
to maintain a normal number of these GnRH neurons in the brain, 
and, accordingly, the blockade of KDR signaling in GT1-7 cells 
compromised SEMA3E-mediated survival signaling. In contrast, 
KDR is not obviously expressed or required by GN11 cells or GnRH 
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SEMA3E. We determined the number of PI-stained cells relative to the 
total number of all Hoechst fluorochrome–positive cells. In some exper-
iments, 1 mg/ml control IgG (R&D Systems) or function-blocking anti-
bodies (goat anti-PLXND1 or goat anti-KDR, see above) were added 1 
hour before SEMA3E treatment. In other experiments, the PI3K inhibi-
tor LY294 (Sigma-Aldrich) was added at 10 μM 1 hour prior to addition 
of SEMA3E. All assays were repeated in 3 independent experiments.
RT-PCR. Total RNA was extracted from GN11 and GT1-7 cells 
with TRIzol (Life Technologies). Single-stranded cDNA was syn-
thesized with AMV reverse transcriptase and random hexamers 
(Promega). PCR was performed as previously described (51). PCR 
products were analyzed by electrophoresis on a 2% agarose gel and 
bands visualized under UV illumination after ethidium bromide 
staining. We used the following oligonucleotides: Plxnd1, 5′-TCCTA-
GACAGCCCTAACCCC-3′ and 5′-AGGCTCAATCGCTCGGATTT-3′; 
Kdr, 5′-ACAGTAGCCGTCAAGATGTT-3′ and 5′-CTACATCACTGAG-
CGATTTC-3′; and Gapdh, 5′-GGCCCCTCTGGAAAGCTGTGG-3′ 
and 5′-TCTTGCTCAGTGTCCTTGCTGGG-3′.
Image processing. To acquire bright-field images, we used a Zeiss 
Axiovert 200 with a Photometrics CoolSNAP ES camera (survival 
assays) or a Leica DM microscope with a DC500 digital camera (AP 
assays, HRP-stained sections). We used a Leica TCS SPE1 confo-
cal microscope to acquire fluorescence images of mouse tissues. All 
images were processed using Photoshop CS4 (Adobe Inc.). In some 
experiments, we acquired bright-field images of ISH patterns and 
confocal images of immunofluorescence staining and converted the 
bright-field images to RGB color mode for superimposition onto the 
confocal images.
Quantitation. To determine the total number of GnRH neurons in 
E14.5 mouse heads, E17.5 mouse brains, or adult mouse brains, 25-μm 
sagittal sections through the entire head/brain of 3 or more animals for 
each genotype were immunolabeled for GnRH and all GnRH-positive 
cells counted in each section, as previously described (5). We deter-
mined the number of apoptotic cells as the average of all cells positive 
for activated caspase-3 in 3 adjacent 20-μm sagittal sections through 
the brain at the level of the GnRH neuron–containing MPOA in 3 inde-
pendent experiments. To compare the abundance of GnRH-positive 
neurites at the ME in WT and mutant brains, we measured the pixel 
intensity of GnRH staining in 20-μm sagittal sections through the ME 
of 3 mice for each genotype. We quantified the number of GnRH and 
PLXND1 double-positive cells in all GnRH-positive cells in 20-μm 
coronal sections of the MPOA as the average of 3 sections in each of 
3 embryos. For survival assays, we determined the percentage of PI- 
positive cells in all Hoechst-positive GN11 or GT1-7 cells for each treat-
ment group in 12 random fields from 3 independent experiments. For 
immunoblotting, 3 independent experiments were performed for each 
condition, the OD of the signal measured with ImageJ software (NIH), 
and the mean pixel intensity calculated.
Statistics. For all experiments, data are expressed as the mean ± 
SEM. To determine statistical significance, we used the unpaired t test 
or, for multiple comparisons, a 1-way ANOVA followed by a Dunnett’s 
post-hoc test. A P value of less than 0.05 was considered statistically 
significant. Statistical analysis was performed using GraphPad Prism4 
(GraphPad Software).
Study approval. All animal experiments were conducted with approval 
from the Animal Welfare and Ethical Review Body of the UCL Institute of 
Ophthalmology and carried our under UK Home Office licence 70/7126. 
R&D Systems). Secondary antibodies used included Alexa Fluor– 
conjugated goat anti-rabbit IgG (1:500; Life Technologies) and, in the 
case of primary goat antibodies, Cy3-conjugated donkey anti-goat Fab 
fragments (1:400; Jackson ImmunoResearch). For immunoperoxi-
dase labeling, cryostat sections of formaldehyde-fixed samples were 
incubated with hydrogen peroxide to quench endogenous peroxidase 
activity before incubation with GnRH primary antibody (1:1,000), fol-
lowed by biotinylated goat anti-rabbit antibody (1:400; Vector Labo-
ratories), and then developed with the ABC kit (Vector Laboratories) 
and DAB (Sigma-Aldrich). Blood vessels were labeled with Alexa Fluor 
488–conjugated isolectin B4 (IB4) (1:400) and nuclei counterstained 
with DAPI (Sigma-Aldrich). In some experiments, we performed ISH 
(49) for Gnrh (gift of Fani Memi, UCL) before immunostaining for 
activated caspase-3 or a TUNEL assay (ApopTag Red; EMD Millipore) 
before immunostaining for GnRH.
Immunoblotting. Cells were lysed in 150 mM NaCl, 50 mM Tris-
HCl (pH 7.4), and 1% Triton X-100, supplemented with protease and 
phosphatase inhibitors (Roche). Lysates were centrifuged at 10,000 g 
for 10 minutes at 4°C and protein concentration determined with the 
Bradford assay (Bio-Rad). The conditioned media of transfected COS 
cells were concentrated by diafiltration with Microcon YH30 tubes 
(EMD Millipore) and diluted 1:2 in Laemmli sample buffer (24). Pro-
tein lysate (20 μg) or concentrated conditioned media (20 μl) were 
used for SDS-PAGE. Proteins were transferred to nitrocellulose mem-
branes (Bio-Rad) and immunoblotted with rabbit anti–phosphorylated 
AKT (Ser473) and rabbit anti-AKT (1:1,000; catalogs 9271 and 9272, 
respectively; Cell Signaling Technology); goat anti-SEMA3E (1:500; 
catalog AF3239; R&D Systems); mouse α-tubulin (1:5,000; catalog 
T568; Sigma-Aldrich); followed by HRP-conjugated anti-rabbit, anti-
goat, or anti-mouse antibodies (1:10,000; catalogs sc-2301, sc-2020, 
and sc-2314; Santa Cruz Biotechnology Inc.).
AP fusion protein–binding assays. To introduce the p.R619C mutation 
into human SEMA3E, we mutated an expression vector containing AP-SE-
MA3E (12) using the QuickChange Lighting Kit (Agilent Technologies) and 
the oligonucleotides 5′-TCCTCTTTTCTTGTCTCACATCCTTTCTGTA-
CAAACCAG-3′ and 5′-CTGGTTTGTACAGAAAGGATGTGAGACAA-
GAAAAGAGGA-3′ (Sigma-Aldrich). Human AP-SEMA3E proteins were 
prepared as previously described (50). GT1-7 cells were fixed for 5 minutes 
in methanol, washed 5 times with PBS, incubated in PBS containing 10% 
FBS for 30 minutes, and then reacted with AP fusion protein for 2 hours at 
room temperature. Cells were then washed for 5 minutes each with PBS, 
fixed with 4% formaldehyde for 2 minutes at room temperature, and 
washed again. Endogenous AP was heat inactivated by incubation at 65°C 
for 3 hours. Cell-bound, heat-stable recombinant AP activity was detected 
as an insoluble reaction product after incubation with nitro blue tetrazolium 
chloride and 5-bromo-4-chloro-3-indolyl phosphate (Roche).
Survival assays. GN11 or GT1-7 cells (gifts of Sally Radovick, Johns 
Hopkins University School of Medicine, Baltimore, Maryland, USA, 
and Pamela Mellon, UCSD, San Diego, California, USA, respectively) 
were seeded in 24-well plates at a density of 5,000 or 20,000 cells 
per well, respectively, and grown for 24 hours in DMEM containing 1 
mM sodium pyruvate, 100 mg/ml streptomycin, 100 U/ml penicillin, 
and 10% FBS (Life Technologies). GN11 and GT1-7 cells were serum 
starved for 48 and 24 hours, respectively, and then grown for a further 
12 hours in serum-free medium in the absence or presence of 10 ng/ml 
recombinant human SEMA3E (R&D Systems) or conditioned media of 
COS cells transfected with vectors encoding AP or AP-tagged human 
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